Profile data is unavailable for this security.
About the company
Shanghai Allist Pharmaceuticals Co Ltd is a China-based company focusing on the field of tumor treatment. The Company has built a research and development pipeline in the field of small molecule targeted drugs for non-small cell lung cancer. The Company has established a complete new drug research and development system, covering all aspects of lead drug discovery and optimization, candidate drug evaluation and establishment, drug preclinical and clinical research, drug registration and application, industrialization and commercialization. The Company has a number of research pipeline projects under development, such as vometinib. Its drugs are used in the fields of blood pressure reduction, anti-tumor, anti-diabetic and gastric acid related diseases.
- Revenue in CNY (TTM)1.62bn
- Net income in CNY487.02m
- Incorporated2004
- Employees870.00
- LocationShanghai Allist Pharmaceuticals Co LtdZhangjiang Hightech ValleySHANGHAI 200023ChinaCHN
- Phone+86 2 151371858
- Fax+86 2 151320233
- Websitehttps://www.allist.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Junshi Biosciences Co Ltd | 1.63bn | -2.02bn | 25.66bn | 2.57k | -- | 4.34 | -- | 15.76 | -2.06 | -2.06 | 1.66 | 6.97 | 0.1348 | 1.05 | 4.11 | 634,034.10 | -18.18 | -18.87 | -23.17 | -23.11 | 64.05 | 69.13 | -134.86 | -88.41 | 1.91 | -215.80 | 0.3018 | -- | 3.38 | 248.39 | 4.38 | -- | 8.36 | -- |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 8.75bn | 928.37m | 26.37bn | 8.22k | 27.84 | 3.09 | -- | 3.01 | 0.6391 | 0.6391 | 6.02 | 5.76 | 0.4511 | 1.08 | 3.46 | 1,064,162.00 | 4.76 | 5.67 | 6.90 | 8.07 | 59.44 | 60.52 | 10.55 | 11.61 | 0.8451 | 5.48 | 0.5047 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
| Bluestar Adisseo Co | 13.53bn | 327.58m | 27.30bn | 2.73k | 83.34 | 1.81 | -- | 2.02 | 0.1222 | 0.1222 | 5.04 | 5.63 | 0.6286 | 4.67 | 7.33 | 4,947,799.00 | 1.52 | 5.28 | 1.85 | 6.94 | 23.81 | 30.31 | 2.42 | 8.76 | 1.04 | 4.30 | 0.1325 | 21.81 | -9.26 | 2.92 | -95.82 | -43.75 | 2.74 | -19.09 |
| Kangmei Pharmaceutical Co Ltd | 4.93bn | 160.40m | 27.31bn | 4.41k | 169.39 | 3.85 | -- | 5.54 | 0.0116 | 0.0116 | 0.3572 | 0.5117 | 0.34 | 1.40 | 2.43 | 1,118,464.00 | 1.12 | -17.60 | 1.69 | -32.24 | 22.71 | -72.78 | 3.28 | -101.19 | 0.8746 | -- | 0.0465 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
| Shanghai Allist Pharmaceuticals Co Ltd | 1.62bn | 487.02m | 29.73bn | 870.00 | 61.04 | 8.15 | -- | 18.34 | 1.08 | 1.08 | 3.60 | 8.10 | 0.4513 | 1.96 | 9.77 | 1,863,318.00 | 13.56 | -6.70 | 14.46 | -7.38 | 94.94 | 96.63 | 30.04 | -49.48 | 8.50 | -- | 0.0006 | -- | 49.22 | 152.37 | 614.22 | -- | 152.72 | -- |
| Gan & Lee Pharmaceuticals | 2.61bn | 386.85m | 30.32bn | 4.48k | 75.87 | 2.78 | -- | 11.62 | 0.6726 | 0.6726 | 4.52 | 18.38 | 0.234 | 0.8926 | 10.97 | 582,412.30 | 3.47 | 8.30 | 3.71 | 8.83 | 72.29 | 85.39 | 14.83 | 26.44 | 7.74 | -- | 0.0006 | 13.65 | 52.31 | 1.78 | 177.37 | -18.30 | 1.50 | -- |
| Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 8.15bn | 973.25m | 31.38bn | 4.62k | 28.05 | 3.91 | -- | 3.85 | 1.27 | 1.27 | 10.60 | 9.09 | 0.744 | 3.12 | 3.24 | 1,765,208.00 | 8.71 | 8.96 | 13.06 | 12.80 | 43.68 | 40.82 | 11.70 | 10.67 | 1.62 | -- | 0.1381 | 56.93 | -0.3266 | 5.28 | 14.49 | 11.93 | -4.33 | 42.22 |
| Humanwell Healthcare Group Co Ltd | 24.67bn | 1.96bn | 33.17bn | 17.68k | 16.84 | 1.89 | -- | 1.34 | 1.21 | 1.21 | 15.25 | 10.73 | 0.6833 | 3.80 | 2.77 | 1,395,473.00 | 7.21 | 6.20 | 13.29 | 12.72 | 45.02 | 42.82 | 10.55 | 9.84 | 1.20 | 31.56 | 0.3293 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
| Autobio Diagnostics Co Ltd | 4.50bn | 1.30bn | 33.77bn | 5.54k | 25.75 | 3.81 | -- | 7.51 | 2.24 | 2.24 | 7.74 | 15.11 | 0.4066 | 2.08 | 4.27 | 811,768.30 | 11.81 | 12.59 | 14.50 | 15.79 | 64.76 | 61.62 | 29.04 | 26.96 | 2.81 | -- | 0.1035 | 46.40 | 0.0457 | 18.15 | 4.28 | 16.70 | 17.03 | 11.28 |
Data as of Mar 13 2024. Currency figures normalised to Shanghai Allist Pharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
8.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Penghua Fund Management Co., Ltd.as of 30 Jun 2023 | 5.71m | 2.76% |
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Sep 2023 | 4.20m | 2.03% |
| China Fund Management Co., Ltd.as of 30 Jun 2023 | 2.10m | 1.02% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2023 | 1.86m | 0.90% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2023 | 1.22m | 0.59% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 1.17m | 0.57% |
| China Asset Management Co., Ltd.as of 30 Jun 2023 | 810.07k | 0.39% |
| Hwabao WP Fund Management Co., Ltd.as of 30 Jun 2023 | 460.48k | 0.22% |
| E Fund Management Co., Ltd.as of 30 Jun 2023 | 379.59k | 0.18% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2023 | 377.53k | 0.18% |
More ▼
Data from 30 Jun 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
